Follow the people · Insider
Tiago Girao
Tiago Girao files insider transactions with the SEC as a chief financial officer of Immunovant (IMVT). We hold 3 disclosed purchases and sales filed since 4 September 2014, 2 of them in the last 90 days.
- Files forIMVT
- Disclosed buys and sells3 in all, 2 in the last 90 days
- Last disclosure24 July 2026
Positions held
4 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 1 May 2025 — 23 July 2026Chief Financial Officer · Immunovant (IMVT)9 Form 4 lines · source: SEC Form 4
- Filed 8 April 2021 — 23 May 2024Director · Landos Biopharma (LABP)7 Form 4 lines · source: SEC Form 4
- Filed 8 March 2017 — 25 July 2018VP & Chief Financial Officer · Cytori Therapeutics (CTYX)8 Form 4 lines · source: SEC Form 4
- Filed 2 September 2014 — 15 June 2016VP & Chief Financial Officer · Cytori Therapeutics (CYTX)11 Form 4 lines · source: SEC Form 4
Everything they disclosed
35 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 6,798 shares of ImmunovantSEC Form 424 July 2026Common Stock · traded 23 July 2026 · filed 24 July 2026
- exercised options over 10,000 shares of ImmunovantSEC Form 426 June 2026Common Stock · traded 26 June 2026 · filed 26 June 2026
- ▼ sold on the open market 10,000 shares of ImmunovantSEC Form 426 June 2026Common Stock · traded 26 June 2026 · filed 26 June 2026
- exercised options over 10,000 shares of Immunovant (a derivative holding)SEC Form 426 June 2026Stock Option (right to buy) · traded 26 June 2026 · filed 26 June 2026
- ▼ sold on the open market 25,760 shares of ImmunovantSEC Form 424 April 2026Common Stock · traded 23 April 2026 · filed 24 April 2026
- was granted 64,968 shares of ImmunovantSEC Form 49 April 2026Common Stock · traded 7 April 2026 · filed 9 April 2026
- was granted 94,002 shares of Immunovant (a derivative holding)SEC Form 49 April 2026Stock Option (right to buy) · traded 7 April 2026 · filed 9 April 2026
- was granted 293,505 shares of Immunovant (a derivative holding)SEC Form 45 May 2025Stock Option (Right to Buy) · traded 1 May 2025 · filed 5 May 2025
- was granted 208,388 shares of ImmunovantSEC Form 45 May 2025Common Stock · traded 1 May 2025 · filed 5 May 2025
- returned to the issuer 1,800 shares of Landos Biopharma (a derivative holding)SEC Form 423 May 2024Stock Option (right to buy) · traded 23 May 2024 · filed 23 May 2024
- returned to the issuer 1,800 shares of Landos Biopharma (a derivative holding)SEC Form 423 May 2024Stock Option (right to buy) · traded 23 May 2024 · filed 23 May 2024
- returned to the issuer 1,800 shares of Landos Biopharma (a derivative holding)SEC Form 423 May 2024Stock Option (right to buy) · traded 23 May 2024 · filed 23 May 2024
- was granted 18,000 shares of Landos Biopharma (a derivative holding)SEC Form 424 May 2023Stock Option (right to buy) · traded 23 May 2023 · filed 24 May 2023
- was granted 18,000 shares of Landos Biopharma (a derivative holding)SEC Form 49 June 2022Stock Option (right to buy) · traded 7 June 2022 · filed 9 June 2022
- was granted 18,000 shares of Landos Biopharma (a derivative holding)SEC Form 418 May 2022Stock Option (right to buy) · traded 16 May 2022 · filed 18 May 2022
- was granted 36,000 shares of Landos Biopharma (a derivative holding)SEC Form 412 April 2021Stock Option (right to buy) · traded 8 April 2021 · filed 12 April 2021
- exercised in-the-money options over 1 share of Cytori Therapeutics (a derivative holding)SEC Form 427 July 2018Subscription Rights (Right to Buy) · traded 25 July 2018 · filed 27 July 2018
- exercised in-the-money options over 1 share of Cytori Therapeutics (a derivative holding)SEC Form 427 July 2018Series C Preferred Stock · traded 25 July 2018 · filed 27 July 2018
- exercised in-the-money options over 1,050 shares of Cytori Therapeutics (a derivative holding)SEC Form 427 July 2018Warrants (Right to Buy) · traded 25 July 2018 · filed 27 July 2018
- exercised in-the-money options over 1 share of Cytori Therapeutics (a derivative holding)SEC Form 429 November 2017Subscription Rights (Right to Buy) · traded 28 November 2017 · filed 29 November 2017
- exercised in-the-money options over 1 share of Cytori Therapeutics (a derivative holding)SEC Form 429 November 2017Series B Preferred Stock · traded 28 November 2017 · filed 29 November 2017
- exercised in-the-money options over 1,800 shares of Cytori Therapeutics (a derivative holding)SEC Form 429 November 2017Warrants (Right to Buy) · traded 28 November 2017 · filed 29 November 2017
- was granted 31,100 shares of Cytori Therapeutics (a derivative holding)SEC Form 417 March 2017Incentive Stock Option (right to buy) · traded 8 March 2017 · filed 17 March 2017
- was granted 42,000 shares of Cytori Therapeutics (a derivative holding)SEC Form 410 March 2017Incentive Stock Option (right to buy) · traded 8 March 2017 · filed 10 March 2017
- exercised in-the-money options over 5,667 shares of Cytori TherapeuticsSEC Form 415 June 2016Common Stock · traded 15 June 2016 · filed 15 June 2016
- exercised in-the-money options over 5,667 shares of Cytori Therapeutics (a derivative holding)SEC Form 415 June 2016Subscription Rights (Right to Buy) · traded 15 June 2016 · filed 15 June 2016
- exercised in-the-money options over 2,833 shares of Cytori Therapeutics (a derivative holding)SEC Form 415 June 2016Warrants (Right to Buy) · traded 15 June 2016 · filed 15 June 2016
- was granted 35,250 shares of Cytori TherapeuticsSEC Form 45 February 2016Common Stock · traded 28 January 2016 · filed 5 February 2016
- was granted 35,250 shares of Cytori TherapeuticsSEC Form 41 February 2016Common Stock · traded 28 January 2016 · filed 1 February 2016
- was granted 349,830 shares of Cytori Therapeutics (a derivative holding)SEC Form 44 January 2016Employee Stock Option · traded 4 January 2016 · filed 4 January 2016
- ▲ bought on the open market 25,000 shares of Cytori TherapeuticsSEC Form 419 August 2015Common Stock · traded 18 August 2015 · filed 19 August 2015
- was granted 120,000 shares of Cytori Therapeutics (a derivative holding)SEC Form 43 February 2015Employee Stock Option · traded 30 January 2015 · filed 3 February 2015
- ▲ bought on the open market 15,889 shares of Cytori TherapeuticsSEC Form 412 November 2014Common Stock · traded 11 November 2014 · filed 12 November 2014
- ▲ bought on the open market 44,111 shares of Cytori TherapeuticsSEC Form 412 November 2014Common Stock · traded 12 November 2014 · filed 12 November 2014
- was granted 150,000 shares of Cytori Therapeutics (a derivative holding)SEC Form 44 September 2014Incentive Stock Option (Right to Buy) · traded 2 September 2014 · filed 4 September 2014
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.